Thoughts on i2O, the Harvard Oral Peptide Delivery Spinout

A new Harvard spinout called i2O Therapeutics has raised $4M in seed funding from Sanofi Ventures and JDRF T1D Fund. Of note, the company was created with the intention of commercializing a novel oral peptide delivery technology initially directed toward diabetes. Below, FENIX provides insight into why i2O may be using oral insulin development as a stepping stone to other molecules and thoughts on how Sanofi may be leveraging its diabetes expertise without committing to R&D.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.